权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of an autologous humanized model of melanoma exploring human thymic education capacity

开发黑色素瘤自体人源化模型，探索人类胸腺教育能力

基本信息

批准号：
9752259
负责人：
Antonio Jimeno
金额：
$ 58.08万
依托单位：
UNIVERSITY OF COLORADO DENVER
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-08-01 至 2021-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9752259
关键词：
Address Adult Affect Antigens Autologous Benchmarking Biological Assay Biological Models Biology Biopsy Bone Marrow CD34 gene CD8-Positive T-Lymphocytes CSF3 gene CTLA4 gene Cells Clinical Data Clinical Trials Data Development Education Engraftment Enrollment Epithelium Exposure to Fibrous capsule of kidney Gene Expression Genetic Genetic Drift Goals Graft vs Tumor Effect Growth Hematopoietic stem cells Home environment Human Immune Immune Targeting Immune checkpoint inhibitor Immune response Immune system Immunity Immunotherapy Implant Malignant Neoplasms Mediating Melanoma Cell Mesenchymal Mesenchymal Stem Cells Modeling Monitor Morphology Mus Natural Killer Cells Nivolumab Pathway interactions Patient Education Patients Plasma Play Predisposition Refractory Resistance Role SLEB2 gene Signal Transduction Source System T-Lymphocyte Testing Therapy trial Thymic Tissue Thymus Gland Time Transplantation Treatment Efficacy Tumor Cell Line Validation anti-tumor immune response cancer cell cohort cytokine drug efficacy experimental study hematopoietic differentiation host neoplasm interaction human disease human model humanized mouse improved improved outcome in vivo in vivo Model induced pluripotent stem cell inhibitor/antagonist macrophage melanoma mouse model neoplastic cell novel strategies patient response personalized medicine precursor cell predicting response prevent prospective reconstitution resistance mechanism response reverse genetics self-renewal therapy outcome treatment response tumor tumor growth

项目摘要

SUMMARY A constraint to studying human cancer is the limited availability of models with appropriate human stroma and immunity. This caveat is particularly relevant for melanoma, given the pivotal role the immune system plays in its development. To address these limitations, we plan to study melanoma biology and therapy in a humanized mouse (HM) model. We initially developed a mis-matched HM (mHM; tumor and hematopoietic stem cells [HSCs] from different sources), and now have generated an autologous HM (aHM; tumor, HSCs and mesenchymal stem cells [MSCs] from the same patient). In HM bearing tumors the human immune and mesenchymal cells from the patient's bone marrow homed into the growing tumor, migrated into the pre- existing mouse stroma, and interacted with the human cancer cells. Tumors grown in HM more closely resembled the originator tumor than those grown in non-HM mice, and the drift in gene expression caused by prior passaging was partially reversed. Signaling in key immune and stroma pathways was more prominent and closely resembled the originator patient in HM vs. non-HM models. The immune cells mounted effective tumor-specific immune responses, mediated by human immune cells including T cells. Significantly, immune responses upon immune therapies in the HM melanoma models showed a correlation with the patient's therapy results. Two salient and under-studied issues limit the wider application of HM: The relevance of the degree of tumor and immune matching, which can affect the faithfulness of immune response, and that can only be appreciated by comparing mHM and aHM. A second criticism to HM is xenogenic education of human T cells on mouse thymic cells, resulting from the lack of a functional human thymus in such models. In this application we will further address the relevance of an autologous versus mis-matched HM to test which approach gives rise to a more representative model of melanoma; secondly, using the same precursor cells from the patient we will reconstitute a functional thymus. The overarching goal of this proposal is to conduct a co-clinical trial where we will accomplish the following: 1) prospectively generate and characterize aHM and mHM from 20 melanoma patients, 2) test which approach yields a more representative melanoma HM model, 3) test in HM the immune drugs (cytotoxic T-lymphocyte-associated protein 4 [CTLA4] and programmed cell death protein 1 [PD-1] inhibitors) that each patient received and correlate with the clinical data, 4) identify the mechanisms involved in resistance to CTLA4/PD-1 inhibitors; and finally as an exploratory Aim in selected cases, we will 5) generate thymic epithelium from the same patient's HSCs that will result in HM with a fully autologous melanoma, thymus and immune system, thus enabling immune cell education in a strictly human context. This project will advance our understanding of the tumor-host interaction in melanoma and human cancer, by better characterizing the interplay between melanoma cells and the immune and stroma systems, leading to the discovery of new approaches to improve personalization of therapy and improve outcomes.

总结